Top

Published in:

Open Access 01-12-2013 | Case report

Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib

Authors: Dennis A Wicherts, Frits van Coevorden, Houke M Klomp, Martine A van Huizum, J Martijn Kerst, Rick LM Haas, Hester H van Boven, JA van der Hage

Published in: World Journal of Surgical Oncology | Issue 1/2013

Abstract

Curative surgical treatment of recurrent, locally advanced dermatofibrosarcoma protuberans is often limited owing to a close relation of the tumor with important anatomical structures. Targeted therapy with imatinib, a tyrosine kinase inhibitor, may cause significant reduction of tumor volume, thereby enabling radical surgery. This treatment strategy, therefore, offers a chance of cure for selected patients with advanced dermatofibrosarcoma protuberans. In addition, preoperative treatment with imatinib may decrease possible disfigurement related to radical surgery for large tumors.

Available only for authorised users

Rutkowski P, Wozniak A, Switaj T: Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma. 2011, 2011: 959132PubMedCentralCrossRefPubMed

Kransdorf MJ: Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol. 1995, 164: 129-134. 10.2214/ajr.164.1.7998525.CrossRefPubMed

Criscione VD, Weinstock MA: Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol. 2007, 56: 968-973. 10.1016/j.jaad.2006.09.006.CrossRefPubMed

Chang CK, Jacobs IA, Salti GI: Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004, 30: 341-345. 10.1016/j.ejso.2003.12.005.CrossRefPubMed

Kimmel Z, Ratner D, Kim JYS, Wayne JD, Rademaker AW, Alam M: Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol. 2007, 14: 2113-2120. 10.1245/s10434-006-9233-3.CrossRefPubMed

Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E: Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol. 1992, 18: 241-248.PubMed

Haas RL, Keus RB, Loftus BM, Rutgers EJ, van Coevorden F, Bartelink H: The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft Tissue Tumours Working Group. Eur J Cancer. 1997, 33: 1055-1060. 10.1016/S0959-8049(97)00026-9.CrossRefPubMed

Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002, 20: 3586-3591. 10.1200/JCO.2002.01.027.CrossRefPubMed

Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED: Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs. 2005, 16: 461-466. 10.1097/00001813-200504000-00014.CrossRefPubMed

10.

McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol. 2005, 23: 866-873. 10.1200/JCO.2005.07.088.CrossRefPubMed

11.

Abbott JJ, Erickson-Johnson M, Wang X, Nascimento AG, Oliveira AM: Gains of COL1A1- PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol. 2006, 19: 1512-1518.PubMed

12.

Llombart B, Monteagudo C, Sanmartín O, López-Guerrero JA, Serra-Guillén C, Poveda A, Jorda E, Fernandez-Serra A, Pellín A, Guillén C, Llombart-Bosch A: Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol. 2011, 65: 564-575. 10.1016/j.jaad.2010.06.020.CrossRefPubMed

Title: Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib
Authors: Dennis A Wicherts
Frits van Coevorden
Houke M Klomp
Martine A van Huizum
J Martijn Kerst
Rick LM Haas
Hester H van Boven
JA van der Hage
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2013
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-11-59

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Mediastinal mature teratoma with complex rupture into the lung, bronchus and skin: a case report

Cerebral iodized lipid embolization via a pulmonary arteriovenous shunt: rare complication of transcatheter arterial embolization for hepatocellular carcinoma

The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection

Laparoscopy-assisted gastrectomy with D2 lymph node dissection for advanced gastric cancer without serosa invasion: a matched cohort study from South China

Investigating citrullinated proteins in tumour cell lines

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy